102,500 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Bought by First Eagle Investment Management LLC

First Eagle Investment Management LLC bought a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 102,500 shares of the medical technology company’s stock, valued at approximately $1,071,000. First Eagle Investment Management LLC owned about 0.07% of Alphatec at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ATEC. Comerica Bank grew its stake in Alphatec by 64.8% during the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after buying an additional 2,534 shares during the last quarter. Van ECK Associates Corp grew its stake in Alphatec by 11.8% during the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock worth $128,000 after buying an additional 1,300 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Alphatec during the 1st quarter worth $141,000. SG Americas Securities LLC grew its stake in Alphatec by 44.6% during the 2nd quarter. SG Americas Securities LLC now owns 14,495 shares of the medical technology company’s stock worth $151,000 after buying an additional 4,472 shares during the last quarter. Finally, Cetera Advisors LLC grew its stake in Alphatec by 15.6% during the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock worth $175,000 after buying an additional 1,720 shares during the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ATEC shares. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Friday, August 30th. Piper Sandler dropped their price target on Alphatec from $17.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Thursday, August 1st. Needham & Company LLC dropped their price target on Alphatec from $23.00 to $13.00 and set a “buy” rating on the stock in a research note on Thursday, August 22nd. Finally, Lake Street Capital dropped their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Alphatec presently has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Insider Buying and Selling

In other Alphatec news, Director David M. Demski purchased 50,000 shares of Alphatec stock in a transaction that occurred on Wednesday, August 21st. The stock was bought at an average price of $5.67 per share, with a total value of $283,500.00. Following the acquisition, the director now owns 288,441 shares of the company’s stock, valued at approximately $1,635,460.47. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.80% of the stock is currently owned by insiders.

Alphatec Stock Performance

Shares of ATEC stock opened at $6.03 on Friday. The stock has a market cap of $843.50 million, a PE ratio of -4.05 and a beta of 1.40. The business has a 50-day simple moving average of $7.40 and a 200-day simple moving average of $10.29. The company has a quick ratio of 1.21, a current ratio of 2.22 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 52-week low of $5.28 and a 52-week high of $17.34.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The company had revenue of $145.57 million during the quarter, compared to analyst estimates of $144.55 million. Alphatec had a negative net margin of 33.48% and a negative return on equity of 816.57%. The business’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.43) EPS. On average, equities analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.